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Abstract
Purpose: Based on previous studies that demonstrated the safety profile and preliminary clinical activity
of prostate specific antigen (PSA) targeted therapeutic vaccines, as well as recent laboratory data
supporting the value of the addition of co-stimulatory molecules B7-1, ICAM-1, and LFA-3 (designated
TRICOM™) to these vaccines, we conducted a Phase I study to evaluate the safety and immunogenicity
of a novel vaccinia and fowlpox vaccine incorporating the PSA gene sequence and TRICOM.
Methods:  In this study, ten patients with androgen independent prostate cancer with or without
metastatic disease were enrolled. Patients were treated with 2 × l08 pfu of a recombinant vaccinia virus
vaccine (PROSTVAC-V) followed by 1 × 109 pfu of the booster recombinant fowlpox virus (PROSTVAC-
F) both with gene sequences for PSA and TRICOM. The mean age of patients enrolled in the study was
70 (range 63 to 79). The mean PSA at baseline was 434 (range 9 – 1424).
Results: There were no deaths, and no Grade 3 or 4 adverse events. The most commonly reported
adverse events, regardless of causality, were injection site reactions and fatigue. One serious adverse event
(SAE) occurred that was unrelated to vaccine; this patient developed progressive disease with a new
sphenoid metastasis. PSA was measured at week 4 and week 8. Four patients had stable disease (with less
than 25% increase in PSA) through the week 8 study period. Anti-PSA antibodies were not induced with
therapy: however, anti-vaccinia titers increased in all patients.
Conclusion: This study demonstrated that vaccination with PROSTVAC-V and PROSTVAC-F combined
with TRICOM is well-tolerated and generated an immune response to vaccinia. Therefore, PROSTVAC-
VF/TRICOM represents a feasible therapeutic approach for further phase II and III study in patients with
prostate cancer.
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Introduction
In 2005, approximately 230,000 new patients were diag-
nosed with prostate cancer, and about 30,000 died,
mostly from metastatic disease [1]. Most patients in the
US are diagnosed with localized or regional disease that is
treated with surgery (e.g., prostatectomy) and/or radia-
tion therapy, including brachytherapy. Despite local treat-
ment, approximately 50% of patients develop recurrent
disease. These patients are generally treated with andro-
gen blockade, which improves pain, and urinary symp-
toms, but is only temporarily effective. Two recently
published phase III studies utilizing taxane-based therapy
for androgen-independent prostate cancer have demon-
strated an improvement in survival [2,3]. Despite this
improvement in therapy, the majority of men will die
from metastatic disease, thus highlighting the need for
novel therapeutic approaches.
Harnessing the immune system to identify and destroy
cancer cells, or immunotherapy, is one such novel
approach. Initial efforts to develop an immune-mediated
treatment for patients with prostate cancer included the
study of pox virus vaccination. In prostate cancer, Eder et
al. treated patients with recombinant vaccinia PSA (rV-
PSA) vaccine and demonstrated safety [4]. Gulley et al.
recently completed a Phase I clinical trial of rV-PSA in 42
patients with metastatic androgen independent prostate
cancer also demonstrating safety and immunological
response [5]. Our prior study demonstrated the safety and
activity of the combined approach of fowlpox and vac-
cinia PSA vaccines without co-stimulatory molecules in a
randomized Phase II trial; this study demonstrated the
safety of this approach and suggested the sequence of vac-
cinia followed by fowlpox was clinically superior [6].
A number of additional co-stimulatory molecules on anti-
gen presenting cells have been identified including ICAM-
1, B7.1, and leukocyte function associated antigen-3 (LFA-
3). Constructs using poxviral vectors (fowlpox and vac-
cinia) have been generated that contain this triad of co-
stimulatory molecule transgenes (designated TRICOM).
Preclinical studies using TRICOM constructs have shown
that they are superior to those constructs that contain only
one or two of the co-stimulatory molecules [7,8]. Phase I
studies have been completed combining CEA-based pox
virus vaccines with TRICOM demonstrating the feasibility
of this approach [9].
This preliminary data provided the justification for a
phase I study to evaluate the safety of vaccinia and fowl-
pox PSA vaccines in combination with TRICOM.
Although poxvirus vaccines expressing PSA and TRICOM
had been previously evaluated in separate trials, the clini-
cal trial reported here used both in a single vector and was
designed as a safety/feasibility trial. The dose of the vac-
cine was selected based on prior studies demonstrating an
acceptable safety profile [6,9].
Materials and methods
Patient eligibility
Men age ≥ 18 yrs with prior small pox immunization were
eligible. The patients had an ECOG performance status of
≤ 2 with life expectancy of at least 6 months. The patients
must have had histologically-proven adenocarcinoma of
the prostate with hormone refractory disease with rising
PSA or with metastatic disease. Patients progressing on
androgen ablation therapy must have been maintained
on LHRH agonist and be off flutamide or bicalutamide for
4 or 6 weeks respectively. Patients who received any prior
chemotherapy were not eligible for this trial. Patients had
to have adequate liver, hematopoetic and renal function
(Hgb>8 g/dl, WBC>2000 cells/mm3, platelet>100,000
cells/mm3, bilirubin<1.5 times ULN, serum creatinine< 2
mg/dl).
Treatment
All patients signed institutional review board (IRB)-
approved informed consent forms prior to undergoing
screening procedures. On day 1, after study personnel
completed the review of eligibility criteria, baseline phys-
ical examination, measurement of vital signs, review of
local laboratory assessments (including PSA), and blood
sampling for immunologic analysis, patients received 1
dose of PROSTVAC-V (the vaccinia virus with gene
sequences for PSA and TRICOM as described below). On
day 29, after study personnel completed physical exami-
nation, vital sign measurements, review of laboratory val-
ues (including PSA), blood sampling for immunologic
analysis, and assessment of adverse events (AEs) and con-
comitant therapy, patients received 1 dose of PROSTVAC-
F (the fowlpox virus with gene sequences for PSA and TRI-
COM as described below). On day 43, study personnel
were to interview patients by telephone to document AEs.
On day 57, patients were to return to the clinic for the
study termination visit, including a physical examination,
vital sign measurements, Eastern Cooperative Oncology
Group Performance Status (ECOG), electrocardiogram
(ECG), laboratory assessments (including PSA), blood
sampling for antibody and immunologic analysis, and
assessment of AEs and concomitant therapy.
Vaccine preparation
PROSTVAC-VF consists of two genetically engineered vac-
cines (recombinant vaccinia or fowlpox virus) adminis-
tered in a sequential regimen. The vaccinia strain used in
PROSTVAC-V is a partially attenuated version of the virus
used for smallpox immunization. Fowlpox is unable to
replicate in human cells but has been shown to be an
effective means of boosting cellular immune responses
initiated with vaccinia. The viral vectors are engineered toJournal of Translational Medicine 2006, 4:1 http://www.translational-medicine.com/content/4/1/1
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contain the gene encoding PSA which contains an altera-
tion in the HLA-A2 specific epitope that is designed to
enhance the immunogenicity of the expressed antigen. In
addition, these viruses both contain the genes encoding
three co-stimulatory molecules, B7.1, ICAM-1 and LFA-3.
The vaccines are a clarified lysate of pox virus-infected pri-
mary chicken embryo dermal cells that has been partially
purified. The product is re-suspended in phosphate-buff-
ered saline with 10% glycerol and stored at -70 degrees C
or colder. Virus is vialed at 0.3 ml/vial at a target concen-
tration of ≥ 109 plaque forming units (pfu)/ml. On the
day of administration the vial is thawed at room temper-
ature and diluted with 0.9% sodium chloride for injection
using a 22 gauge needle. The dose of vaccine was based on
safety data from previous poxvirus vaccine trials evaluat-
ing poxviruses expressing PSA and poxviruses expressing
TRICOM with CEA.
Patient assessment
The current study was a phase I trial with assessment of
dose limiting toxicity (DLT) at this single planned dose
level, as defined by any grade 2 or greater allergic reaction
of asymptomatic bronchospasm and/or generalized urti-
caria, or autoimmune response; or any grade 3 or greater
hematologic or non-hematologic adverse event that is
attributable to vaccine. Although assessment of safety was
the primary end point, we also reported biochemical pro-
gression as an increase in PSA of greater than 25% from
baseline, and stable disease as a PSA increase of ≤ 25%
and decrease <50%. Patients were considered to have a
response if they experienced ≥ 50% decrease in PSA.
Antibody measurement
Anti-vaccinia, anti-fowlpox, and anti-PSA antibody
response were evaluated using ELISA specific for vaccinia,
fowlpox, and PSA. Ninety six well microtiter plates were
coated overnight with PSA protein from human seminal
fluid (Biodesign), parental vaccinia lysate (TBC-Wyeth),
or parental fowlpox lysate (TBC-FPV). The next day the
plates were blocked, washed and two-fold serial dilutions
of patient sera, controls, and naïve sera were added to the
appropriate wells in duplicate. Following an overnight
incubation binding antibody was detected using a conju-
gated anti-IgG secondary antibody and the color devel-
oped with the appropriate substrate. The ELISA plates
were analyzed using a Molecular Devices SpectraMax®
plate reader.
The titer was determined for each sample. The titer is
defined as the reciprocal of the dilution with an absorb-
ance of three times the absorbance of the appropriate con-
trol, which is tested at a single dilution. Human naïve
vaccinia and human naïve fowlpox sera were used as con-
trols for the poxvirus ELISAs. Each patient's pre-vaccina-
tion serum sample was used as the control for the PSA
ELISA. A positive response was defined as a two-fold
increase of the post-immunization sample compared to
the pre-immunization sample.
Statistical methods
The sample size was chosen to provide an adequate initial
demonstration of safety and tolerability. Immune and
PSA response data was summarized as a mean value for all
patients at each time point. The planned dose was to be
considered the recommended phase II dose if < 2 patients
out of 10 had a DLT. Further dose escalation was not felt
to be necessary, given prior studies demonstrating
immune effects using similar dosing without TRICOM.
Results
Patient demographics
A total of 10 men with androgen independent prostate
cancer with biochemical only or objective progression
were enrolled (Table 1). Patients received one dose of
PROSTVAC-V (vaccinia virus) followed by a booster dose
of PROSTVAC-F (fowlpox virus) after 4 weeks. The mean
age of patients enrolled in the study was 70 (range 63 to
79). Nine patients were Caucasian and one was African
American. The mean PSA at baseline was 434 (range 9 –
1424). The mean anti-vaccinia titer at baseline was 700
(range 200–1600). The patients were followed up to 8
weeks after the initial dose.
Toxicity
No patients experienced dose limiting toxicity and there
were no deaths on study. Nine patients reported 37
adverse events. There were no Grade 3 or 4 adverse events.
Table 1: Patient Demographics
Age (years)
n1 0
Mean 69.6
Range 63–79
Race/Ethnicity
n1 0
Caucasians 9
African Americans 1
Baseline PSA (ng/mL)
n1 0
Mean 434
Range 9–1424
Baseline Anti-Vaccinia Titer
n1 0
Mean 700
Range 200–1600Journal of Translational Medicine 2006, 4:1 http://www.translational-medicine.com/content/4/1/1
Page 4 of 5
(page number not for citation purposes)
The most commonly reported adverse events, regardless
of causality, were injection site reactions and fatigue.
Grade 2 adverse events experienced by at least two
patients that were assessed as being least remotely related
to study drug were diarrhea, cervical lymphadenopathy,
paresthesia and hypoesthesia (left facial numbness). One
serious adverse event (SAE) occurred that was unrelated to
vaccine. This patient developed a new sphenoid metasta-
sis, attributed to progressive disease rather than vaccine
administration.
Biochemical/clinical Effect
The patients were followed only for a period of 8 weeks.
PSA was measured at end of 4 weeks and 8 weeks (Table
2). Four patients had stable PSA through the 8 week study
period (two patients had minimally decreased PSA levels
at week 4, with one decrease sustained through week 8
(patients 002/009 and 003/011, respectively)). Patient
002–005 developed neurologic symptoms and MRI
revealed a new sphenoid metastasis.
Immune response
All the patients were followed for immune response.
None of the patients mounted any anti-PSA antibody
response when evaluated by ELISA (data not shown). In
contrast, anti-vaccinia titers increased in patients as meas-
ured by seroconversion at Day 15 (14 days post-vaccina-
tion; Table 3 and Figure 1). The mean anti-vaccinia titer at
baseline was 700 (range 200–1600) likely due to prior
smallpox vaccination. At the end of eight weeks the mean
anti-vaccinia titer increased to 2720 (range 800–6400).
One of the 10 patients developed an antibody response to
fowlpox, as measured by seroconversion at Day 57 (28
days post-vaccination), (data not shown).
Discussion
The current study demonstrated that sequential vaccina-
tions with PROSTVAC-V followed by PROSTVAC-F,
including gene sequences for PSA and the three co-stimu-
latory molecules termed TRICOM, could be administered
safely to men with androgen-independent prostate can-
cer. All patients demonstrated a rise in anti-vaccinia virus
antibody titers without a detectable increase in anti-PSA
titers. Four patients had stable post-vaccination PSA val-
ues at 8 week follow-up, with minimal decrease in two
patients.
As a means to induce an immune response, the poxviruses
are among the most commonly studied vectors for gene
delivery [10]. Advantages of the poxviral vectors include
the large size of the genomes, which have allowed as
many as seven transgenes to be expressed in a single vac-
cinia virus vector, and greater immunogenicity of
expressed proteins compared to native protein, attributed
to the inflammatory response triggered against highly
immunogenic viral proteins. PSA has also been com-
monly studied as an immunological target in prostate
cancer [11,12]. Phase I clinical trials have evaluated the
safety and biological effects of a vaccinia virus expressing
human PSA in patients with prostate cancer without TRI-
COM [2-4]. Our prior study using fowlpox and vaccinia
PSA-based vaccines without TRICOM in sequence demon-
strated forty-one of sixty-four (64.1%) evaluable patients
were free of PSA or clinical progression at 6 months with
a trend favoring the arm with vaccinia followed by fowl-
pox vaccines. Although PSA declines of >50% were not
noted, in one treatment arm, PSA doubling time changed
from 4.5 months to 30.9 months supporting the hypoth-
esis that the vaccine was slowing disease progression [6].
In the current study, patients were not assessed prior to
therapy to determine changes in PSA velocity, since the
main endpoint was to demonstrate safety of the PSA vac-
cine prime and boost approach with TRICOM for future
studies.
A number of additional co-stimulatory molecules on anti-
gen presenting cells have been identified including ICAM-
1, B7.1, and LFA-3. Constructs using poxviral vectors
(fowlpox and vaccinia) have been generated that contain
this triad of co-stimulatory molecule transgenes, and have
been given the designation TRICOM. Preclinical studies
Table 2: Effect on PSA
Patient ID Baseline Day 29 (± 2) Day 57 (± 2)
002–005 1353.10 1826.57 3150.50
002–007 89.00 91.22 108.53
002–008 108.50 190.23 265.74
002–009 1181.00 1141.30 1266.00
003-001 26.90 32.00 36.30
003-002 89.50 138.60 175.50
003-003 27.70 32.30 32.80
003–004 31.80 54.90 63.70
003–010 9.00 9.40 13.30
003–011 1424.00 1359.00 1268.00
Table 3: Anti-Vaccinia Titers
Patient ID Baseline Day 15
(± 2)
Day 29
(± 2)
Day 57
(± 2)
002–005 1600 12800 12800 3200
002–007 800 1600 1600 1600
002–008 200 3200 3200 1600
002–009 400 1600 1600 1600
003-001 800 3200 3200 1600
003-002 400 1600 1600 800
003-003 800 6400 6400 3200
003–004 200 3200 1600 800
003–010 1600 3200 3200 6400
003–011 200 6400 25600 6400Journal of Translational Medicine 2006, 4:1 http://www.translational-medicine.com/content/4/1/1
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using TRICOM constructs have suggested that they are
superior to those constructs that contain only one or two
of the co-stimulatory molecules [7,8]. Studies have been
completed combining CEA pox vaccines with TRICOM
demonstrating safety of this approach. A Phase I clinical
study has recently been completed employing vaccinia-
CEA/TRICOM and fowlpox-CEA/TRICOM in a diversified
prime and boost regimen, with most patients enrolled
with GI malignancies [9]. The current study demonstrates
that the PSA-based vaccine TRICOM has minimal toxicity.
In contrast to previous trials using vaccinia virus or heter-
ologous prime-boost vaccination with vaccinia followed
by fowlpox viruses expressing PSA without TRICOM,
which demonstrated effects on PSA velocity, this trial did
not utilize repeated booster immunizations [4,6]. The cur-
rent trial was designed to test the safety and feasibility of
co-expressing PSA and TRICOM in patients with andro-
gen-independent prostate cancer. A larger trial would be
needed to determine clinical endpoints and should
include on-going booster vaccinations in responding
patients to determine long-term toxicity, biochemical
response, and disease-free survival.
The current study also demonstrated increased anti-vac-
cinia antibody without any increase in anti-PSA antibody.
In prior trials, an interferon-γ ELISPOT assay was used to
monitor T cell responses against PSA in patients who were
HLA-*A0201 positive, since there is a well defined HLA-
A2-restricted peptide for in vitro targeting. Patients
enrolled in the current trial were not HLA restricted and a
validated T cell assay was not available. Therefore, we
chose to measure the anti-PSA antibody response. Similar
to previous trials, we failed to demonstrate an increase in
anti-PSA antibody. In the randomized Eastern Coopera-
tive Oncology Group Phase II study, there were no signif-
icant increases in anti-PSA antibody titers detected despite
46% of patients demonstrating an increase in PSA-reactive
T-cells, and 45% biochemical progression-free survival at
19 months [6]. The reason for the absence of anti-PSA
antibody response may relate to the sensitivity of the assay
or to the presence of antigen-antibody complexes in the
serum of men with elevated levels of PSA. Future studies
with these vaccines may need to focus on the assessment
of PSA-reactive T-cells and the determination of circulat-
ing immune complexes.
In summary, these data demonstrated the feasibility and
safety of the PSA vaccine using a prime with vaccinia
(PROSTVAC-V) followed by a boost with fowlpox (PROS-
TVAC-F) in which both vectors contain the gene
sequences for the three co-stimulatory molecules, B7-1,
ICAM-1, and LFA-3 (TRICOM) in men with androgen-
independent prostate cancer. These data support further
assessment of this vaccine approach in phase II and phase
III clinical studies.
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